All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-06-12T15:49:42.000Z

ASCO 2018 | Ibrutinib plus venetoclax shows promising efficacy in CLL

Jun 12, 2018
Share:

Bookmark this article

On Sunday 3rd June an oral abstract session took place at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 7502 was presented by William Wierda, The University of Texas MD Anderson Cancer Center, Texas, on the phase II CAPTIVATE study (NCT02910583).

The study assessed the use of ibrutinib plus venetoclax as first-line treatment in chronic lymphocytic leukemia (CLL). A total of 164 patients with treatment-naïve CLL were included in the trial. They were treated with 420mg ibrutinib once daily for 3 cycles and then intravenous venetoclax up to 400mg once daily for 12 cycles. If minimal residual disease (MRD) was confirmed detectable then patients were randomized to receive either placebo or ibrutinib. If MRD was undetectable, not confirmed then patients were randomized to receive either ibrutinib or ibrutinib plus venetoclax (I+V).

Key Findings

  • It was found that 3 cycles of ibrutinib lead-in reduced tumor lysis syndrome (TLS) risk and bulky disease. Additionally, out of 40 patients with high baseline TLS risk, 90% shifted to medium or low risk
  • 77% patients receiving I+V had undetectable MRD in peripheral blood after 6 cycles and after 12 cycles, 79% had confirmed undetectable MRD
  • No new safety signals emerged and adverse events were consistent with the historic safety profiles

Dr Wierda concluded that “these early results show a highly active and safe treatment with 12 cycles of combined treatment with ibrutinib and venetoclax.” See below for an interview with Dr Wierda discussing the study results.

Expert Opinion

  1. Wierda W., et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). Abstract 7502. 2018 ASCO Annual Meeting, Chicago, Illinois

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox